<DOC>
	<DOCNO>NCT00032903</DOCNO>
	<brief_summary>Gimatecan® Sigma-Tau Research 's new , potent , oral Topoisomerase I inhibitor . Drugs class play crucial role destroy DNA replication tumor . We conduct study determine Maximum Tolerated Dose compound . In addition , plan assess drug 's ability affect evolution malignant glioma , give capsule , rather intravenous injection .</brief_summary>
	<brief_title>This Early Study Investigate Effect Gimatecan® Adults With Malignant Glioma .</brief_title>
	<detailed_description />
	<mesh_term>Glioma</mesh_term>
	<criteria>Inclusion criterion : Histologically confirm diagnosis recurrent primary malignant glioma Life expectancy least 3 month normal hematological , liver renal function Exclusion criterion : Pregnant lactating patient Participation investigate drug study within 4 week precede treatment start concurrent treatment anticancer therapy Gastrointestinal dysfunction could alter absorption motility</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Malignant Glioma , Camptothecin , Pharmacokinetics</keyword>
</DOC>